InterPAD - DETAILS

trichostatin A, 58880-19-6, TSA, Trichostatin A (TSA), Trichostatin, (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide, Antibiotic A-300, (R)-Trichostatin A, CHEBI:46024, C17H22N2O3, (R,2E,4E)-7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide, GNF-PF-1011, 3X2S926L3Z, 58880-19-6 (R-isomer), 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-, 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, MFCD03848392, A-300-I, (2E,4E,6R)-7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, [R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, Trichostatin-A, Tricostatin A, 2,4-Heptadienamide,7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-, 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE, 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-, 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-, TSN, Trichostatina, trichostatine a, UNII-3X2S926L3Z, Trichlostatin A, Trichostatin(s), DTXSID6037063, NSC-311042, (2E,4E,6R)-7-(4-dimethylaminophenyl)-4,6-dimethyl-7-oxo-hepta-2,4-dienehydroxamic acid, (2E,4E,6R)-7-(4-Dimethylaminophenyl)-N-hydroxy-4,6-dimethyl-7-oxo-hepta-2,4-dienamide, (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, 2,4-heptadienamide; [R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; (R)-Trichostatin A; TSA;, Trichostatin A,TSA, NCGC_TSA, 1c3r, 3f0r, TRICHOSTATIN A [MI], SCHEMBL19886, MLS006011095, SGCTO-002, SCHEMBL675951, GTPL7005, VTR297, CHEBI:93196, VTR-297, BCPP000035, HMS1362L09, HMS1792L09, HMS1990L09, HMS3403L09, HMS3649O20, BCP01776, EX-A1665, BDBM50005711, HB1402, LMPK01000055, s1045, Trichostatin A from Streptomyces sp., AKOS015899840, CCG-208142, CCG-208681, CS-0499, DB04297, NSC 311042, NCGC00162453-01, NCGC00162453-02, NCGC00162453-03, NCGC00162453-04, NCGC00162453-05, NCGC00162453-15, 3C10, AC-35470, AS-74315, HY-15144, PD119680, SMR004702883, FT-0698647, NS00034030, SW219664-1, T2477, A25618, M02571, Q425894, SR-05000013796, Q-201864, SR-05000013796-3, BRD-K68202742-001-04-1, BRD-K68202742-001-05-8, Trichostatin A, >=98% (HPLC), from Streptomyces sp., Trichostatin A, Streptomyces sp. - CAS 58880-19-6, Trichostatin A??, Vetec(TM) reagent grade, from Streptomyces sp., >=98%, (2E,4E,6R)-7-(4-(Dimethylamino)phen yl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamid e, 7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6R-dimethyl-7-oxo-2E,4E-heptadienamide, 2,4-HEPTADIENAMIDE, 7-(4-(DIMETHYLAMINO)PHENYL)-N-HYDROXY-4,6-DIMETHYL-7-OXO-,(2E,4E,6R)-, 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)- (9CI), 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, [R-(E,E)]-

No.	Title	Href
1	Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. Biomed Pharmacother. 2015 Aug;74:257-64. doi: 10.1016/j.biopha.2015.08.017.	`Click`
2	Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics. 2012 Oct;7(10):1161-72. doi: 10.4161/epi.22070.	`Click`

No.

Title

Href

Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. Biomed Pharmacother. 2015 Aug;74:257-64. doi: 10.1016/j.biopha.2015.08.017.

Click

Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics. 2012 Oct;7(10):1161-72. doi: 10.4161/epi.22070.

Click

Name	Trichostatin A
PubChem CID	444732
Molecular Weight	302.37g/mol
Synonyms	trichostatin A, 58880-19-6, TSA, Trichostatin A (TSA), Trichostatin, (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide, Antibiotic A-300, (R)-Trichostatin A, CHEBI:46024, C17H22N2O3, (R,2E,4E)-7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide, GNF-PF-1011, 3X2S926L3Z, 58880-19-6 (R-isomer), 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-, 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, MFCD03848392, A-300-I, (2E,4E,6R)-7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, [R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, Trichostatin-A, Tricostatin A, 2,4-Heptadienamide,7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-, 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE, 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-, 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-, TSN, Trichostatina, trichostatine a, UNII-3X2S926L3Z, Trichlostatin A, Trichostatin(s), DTXSID6037063, NSC-311042, (2E,4E,6R)-7-(4-dimethylaminophenyl)-4,6-dimethyl-7-oxo-hepta-2,4-dienehydroxamic acid, (2E,4E,6R)-7-(4-Dimethylaminophenyl)-N-hydroxy-4,6-dimethyl-7-oxo-hepta-2,4-dienamide, (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, 2,4-heptadienamide; [R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; (R)-Trichostatin A; TSA;, Trichostatin A,TSA, NCGC_TSA, 1c3r, 3f0r, TRICHOSTATIN A [MI], SCHEMBL19886, MLS006011095, SGCTO-002, SCHEMBL675951, GTPL7005, VTR297, CHEBI:93196, VTR-297, BCPP000035, HMS1362L09, HMS1792L09, HMS1990L09, HMS3403L09, HMS3649O20, BCP01776, EX-A1665, BDBM50005711, HB1402, LMPK01000055, s1045, Trichostatin A from Streptomyces sp., AKOS015899840, CCG-208142, CCG-208681, CS-0499, DB04297, NSC 311042, NCGC00162453-01, NCGC00162453-02, NCGC00162453-03, NCGC00162453-04, NCGC00162453-05, NCGC00162453-15, 3C10, AC-35470, AS-74315, HY-15144, PD119680, SMR004702883, FT-0698647, NS00034030, SW219664-1, T2477, A25618, M02571, Q425894, SR-05000013796, Q-201864, SR-05000013796-3, BRD-K68202742-001-04-1, BRD-K68202742-001-05-8, Trichostatin A, >=98% (HPLC), from Streptomyces sp., Trichostatin A, Streptomyces sp. - CAS 58880-19-6, Trichostatin A??, Vetec(TM) reagent grade, from Streptomyces sp., >=98%, (2E,4E,6R)-7-(4-(Dimethylamino)phen yl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamid e, 7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6R-dimethyl-7-oxo-2E,4E-heptadienamide, 2,4-HEPTADIENAMIDE, 7-(4-(DIMETHYLAMINO)PHENYL)-N-HYDROXY-4,6-DIMETHYL-7-OXO-,(2E,4E,6R)-, 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)- (9CI), 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, [R-(E,E)]-
Drug Type	Small molecule
Formula	C₁₇H₂₂N₂O₃
SMILES	CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C
InChI	1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1
InChIKey	RTKIYFITIVXBLE-QEQCGCAPSA-N
CAS Number	58880-19-6
ChEMBL ID	CHEMBL99
ChEBI ID	CHEBI:46024
TTD ID	D0NF6F
Drug Bank ID	DB04297
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Silibinin, Trichostatin A
Partner Name	Silibinin
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Expression	BIRC5	hsa332
Gene Regulation	Down-regulation	Expression	CCNA2	hsa890
In Vitro Model	BxPC-3	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0186
	PaTu 8988s	Pancreatic adenocarcinoma	Homo sapiens (Human)	CVCL_1846
	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0480
	Capan-2	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0026
Result	Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells

Pair Name	Silibinin, Trichostatin A
Partner Name	Silibinin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCNB1	hsa891
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Expression	POLD1	hsa5424
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	NCI-H1299	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0060
	NCI-H358	Minimally invasive lung adenocarcinoma	Homo sapiens (Human)	CVCL_1559
	NCI-H322	Minimally invasive lung adenocarcinoma	Homo sapiens (Human)	CVCL_1556
In Vivo Model	Six week old athymic (nu/nu) male nude mice were subcutaneously injected with about three million exponentially growing H1299 cells mixed with equal volume (1:1) of matrigel on the right flank of each mouse.
Result	Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)